Lv2
192 积分 2023-03-14 加入
Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
7小时前
已完结
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
8小时前
已完结
Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment
8小时前
已完结
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
9小时前
已完结
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
1天前
已完结
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
23天前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已完结
2645 Osimertinib after chemoradiotherapy in unresectable stage III EGFRm NSCLC: chemoradiotherapy regimens and radiation pneumonitis in LAURA (NCT03521154)
1个月前
已关闭
2645 Osimertinib after chemoradiotherapy in unresectable stage III EGFRm NSCLC: chemoradiotherapy regimens and radiation pneumonitis in LAURA (NCT03521154)
1个月前
已关闭
Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance
1个月前
已完结
皖公网安备34019202002308
